Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2566.75
(4.01%)
INR 2566.75
(4.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 42.08 Billion INR | 12.45% |
| 2022 | 37.42 Billion INR | 13.96% |
| 2021 | 32.84 Billion INR | 15.35% |
| 2020 | 28.47 Billion INR | 11.13% |
| 2019 | 25.61 Billion INR | 27.05% |
| 2018 | 20.16 Billion INR | -2.09% |
| 2017 | 20.59 Billion INR | 7.47% |
| 2016 | 19.16 Billion INR | 12.23% |
| 2015 | 17.07 Billion INR | 17.35% |
| 2014 | 14.55 Billion INR | 23.2% |
| 2013 | 11.81 Billion INR | 28.12% |
| 2012 | 9.21 Billion INR | 36.09% |
| 2011 | 6.77 Billion INR | 34.17% |
| 2010 | 5.04 Billion INR | 23.83% |
| 2009 | 4.07 Billion INR | 16.71% |
| 2008 | 3.49 Billion INR | 12.92% |
| 2007 | 3.09 Billion INR | 19.91% |
| 2006 | 2.58 Billion INR | 12.32% |
| 2005 | 2.29 Billion INR | 15.68% |
| 2004 | 1.98 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 11.86 Billion INR | 3.64% |
| 2024 Q1 | 11.44 Billion INR | 8.62% |
| 2023 Q4 | 10.54 Billion INR | -4.62% |
| 2023 Q1 | 10.21 Billion INR | 15.79% |
| 2023 Q2 | 10.28 Billion INR | 0.72% |
| 2023 FY | 42.08 Billion INR | 12.45% |
| 2023 Q3 | 11.05 Billion INR | 7.46% |
| 2022 Q4 | 8.81 Billion INR | -9.25% |
| 2022 FY | 37.42 Billion INR | 13.96% |
| 2022 Q2 | 9.38 Billion INR | -1.35% |
| 2022 Q3 | 9.71 Billion INR | 3.59% |
| 2022 Q1 | 9.5 Billion INR | 16.9% |
| 2021 FY | 32.84 Billion INR | 15.35% |
| 2021 Q4 | 8.13 Billion INR | -2.92% |
| 2021 Q1 | 7.47 Billion INR | 4.74% |
| 2021 Q3 | 8.37 Billion INR | -5.3% |
| 2021 Q2 | 8.84 Billion INR | 18.29% |
| 2020 Q3 | 7.48 Billion INR | 4.59% |
| 2020 Q4 | 7.14 Billion INR | -4.62% |
| 2020 FY | 28.47 Billion INR | 11.13% |
| 2020 Q1 | 6.68 Billion INR | 1.88% |
| 2020 Q2 | 7.15 Billion INR | 7.14% |
| 2019 Q3 | 6.51 Billion INR | 1.31% |
| 2019 Q2 | 6.42 Billion INR | 5.04% |
| 2019 Q1 | 6.11 Billion INR | 28.49% |
| 2019 FY | 25.61 Billion INR | 27.05% |
| 2019 Q4 | 6.55 Billion INR | 0.72% |
| 2018 FY | 20.16 Billion INR | -2.09% |
| 2018 Q4 | 4.76 Billion INR | -1.83% |
| 2018 Q3 | 4.85 Billion INR | -10.84% |
| 2018 Q2 | 5.44 Billion INR | 6.48% |
| 2018 Q1 | 5.1 Billion INR | -3.64% |
| 2017 Q2 | 5.4 Billion INR | 14.22% |
| 2017 Q1 | 4.73 Billion INR | -0.77% |
| 2017 FY | 20.59 Billion INR | 7.47% |
| 2017 Q4 | 5.3 Billion INR | -9.67% |
| 2017 Q3 | 5.87 Billion INR | 8.64% |
| 2016 Q3 | 5.33 Billion INR | 3.35% |
| 2016 Q2 | 5.15 Billion INR | 9.51% |
| 2016 Q1 | 4.71 Billion INR | 9.39% |
| 2016 FY | 19.16 Billion INR | 12.23% |
| 2016 Q4 | 4.76 Billion INR | -10.56% |
| 2015 Q4 | 4.3 Billion INR | -8.92% |
| 2015 FY | 17.07 Billion INR | 17.35% |
| 2015 Q2 | 4.37 Billion INR | 11.84% |
| 2015 Q3 | 4.72 Billion INR | 8.02% |
| 2015 Q1 | 3.91 Billion INR | 10.67% |
| 2014 Q1 | 3.21 Billion INR | 0.0% |
| 2014 Q4 | 3.53 Billion INR | -13.3% |
| 2014 FY | 14.55 Billion INR | 23.2% |
| 2014 Q3 | 4.07 Billion INR | 9.68% |
| 2014 Q2 | 3.71 Billion INR | 15.58% |
| 2013 FY | 11.81 Billion INR | 28.12% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 9.21 Billion INR | 36.09% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 6.77 Billion INR | 34.17% |
| 2010 FY | 5.04 Billion INR | 23.83% |
| 2009 FY | 4.07 Billion INR | 16.71% |
| 2008 FY | 3.49 Billion INR | 12.92% |
| 2007 FY | 3.09 Billion INR | 19.91% |
| 2006 FY | 2.58 Billion INR | 12.32% |
| 2005 FY | 2.29 Billion INR | 15.68% |
| 2004 FY | 1.98 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 91.322% |
| NATCO Pharma Limited | 40.02 Billion INR | -5.165% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -300.313% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -1523.455% |
| Achyut Healthcare Limited | 61.36 Million INR | -68480.391% |
| Alkem Laboratories Limited | 126.67 Billion INR | 66.776% |
| Alpa Laboratories Limited | 1.08 Billion INR | -3770.47% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 31.141% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -224.864% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 85.338% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -789.005% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -446.412% |
| Brooks Laboratories Limited | 794.86 Million INR | -5194.901% |
| Divi's Laboratories Limited | 78.45 Billion INR | 46.352% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 84.924% |
| Eris Lifesciences Limited | 20.09 Billion INR | -109.478% |
| FDC Limited | 19.42 Billion INR | -116.615% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 64.373% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -84.333% |
| Granules India Limited | 45.06 Billion INR | 6.605% |
| Gufic Biosciences Limited | 8.06 Billion INR | -421.742% |
| Hester Biosciences Limited | 3.04 Billion INR | -1281.962% |
| Indoco Remedies Limited | 17.89 Billion INR | -135.196% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -228.574% |
| Ipca Laboratories Limited | 76.22 Billion INR | 44.785% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -1916.612% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -8247.054% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -3933.843% |
| Laurus Labs Limited | 50.01 Billion INR | 15.856% |
| Lupin Limited | 200.1 Billion INR | 78.968% |
| Mankind Pharma Limited | 103.34 Billion INR | 59.276% |
| Medicamen Biotech Limited | 1.79 Billion INR | -2247.219% |
| Medico Remedies Limited | 1.44 Billion INR | -2804.147% |
| Megasoft Limited | 373.95 Million INR | -11154.65% |
| Piramal Pharma Limited | 81.71 Billion INR | 48.493% |
| RPG Life Sciences Limited | 5.82 Billion INR | -623.084% |
| Sigachi Industries Limited | 3.98 Billion INR | -954.931% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -5471.108% |
| Unichem Laboratories Limited | 16.57 Billion INR | -153.932% |
| Wanbury Limited | 5.75 Billion INR | -631.123% |
| Windlas Biotech Limited | 6.3 Billion INR | -567.037% |
| ZIM Laboratories Limited | 3.67 Billion INR | -1045.463% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 77.874% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -265.574% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -899.147% |
| Bal Pharma Limited | 3.39 Billion INR | -1140.704% |
| Strides Pharma Science Limited | 40.51 Billion INR | -3.89% |
| Venus Remedies Limited | 5.91 Billion INR | -611.592% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -131.82% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -149.911% |
| Shilpa Medicare Limited | 11.51 Billion INR | -265.465% |
| Aarti Drugs Limited | 25.28 Billion INR | -66.446% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -98.621% |
| Suven Life Sciences Limited | 116.92 Million INR | -35893.723% |
| Ind-Swift Limited | 5.02 Billion INR | -737.607% |
| Valiant Laboratories Limited | 1.82 Billion INR | -2211.751% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | -20.795% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -239.853% |
| Themis Medicare Limited | 3.81 Billion INR | -1002.447% |
| Hikal Limited | 17.84 Billion INR | -135.835% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 60.316% |
| Sequent Scientific Limited | 13.69 Billion INR | -207.265% |
| Novartis India Limited | 3.35 Billion INR | -1156.069% |
| Wockhardt Limited | 27.89 Billion INR | -50.904% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 37.211% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -10412.498% |
| Neuland Laboratories Limited | 15.58 Billion INR | -170.035% |
| Morepen Laboratories Limited | 17.01 Billion INR | -147.295% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -2626.334% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -1041.826% |